Vireo Growth (OTCMKTS:VREOD – Get Free Report) is one of 907 public companies in the “Pharmaceuticals” industry, but how does it contrast to its competitors? We will compare Vireo Growth to similar companies based on the strength of its valuation, analyst recommendations, institutional ownership, earnings, risk, dividends and profitability.
Institutional and Insider Ownership
33.0% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.8% of Vireo Growth shares are owned by insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Vireo Growth and its competitors gross revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Vireo Growth | $268.77 million | -$68.11 million | -3.02 |
| Vireo Growth Competitors | $3.53 billion | $3.12 billion | 537.93 |
Volatility and Risk
Vireo Growth has a beta of 1.78, suggesting that its stock price is 78% more volatile than the S&P 500. Comparatively, Vireo Growth’s competitors have a beta of -3.22, suggesting that their average stock price is 422% less volatile than the S&P 500.
Profitability
This table compares Vireo Growth and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vireo Growth | -23.37% | -19.76% | -7.15% |
| Vireo Growth Competitors | -2,342.26% | -248.60% | -16.78% |
Analyst Recommendations
This is a breakdown of current ratings and target prices for Vireo Growth and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vireo Growth | 1 | 0 | 0 | 0 | 1.00 |
| Vireo Growth Competitors | 7618 | 13715 | 25595 | 996 | 2.42 |
As a group, “Pharmaceuticals” companies have a potential upside of 28.87%. Given Vireo Growth’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Vireo Growth has less favorable growth aspects than its competitors.
Summary
Vireo Growth competitors beat Vireo Growth on 9 of the 13 factors compared.
About Vireo Growth
Goodness Growth Holdings, Inc. operates as a cannabis company in the United States. The company cultivates, processes, and distributes medical and adult-use cannabis products. It sells cannabis products through its network of Green Goods and other Goodness Growth branded retail dispensaries and third-party dispensaries in Maryland, Minnesota, and New York. The company was formerly known as Vireo Health International Inc. and changed its name to Goodness Growth Holdings, Inc. in June 2021. Goodness Growth Holdings, Inc. is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Vireo Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vireo Growth and related companies with MarketBeat.com's FREE daily email newsletter.
